• 1
    Custer B, Sullivan S, Hazlet T, et al. Global epidemilogy of hepatitis B virus. J Clin Gastroenterol 2004;38 (Suppl.):S15868.
  • 2
    Shaw T, Locarnino S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect 2004;2: 85371.
  • 3
    Guan ZQ, Dong ZH, Wang QH, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004;38(Suppl.):S1758.
  • 4
    Liaw YF, Leung NW, Chang TT, et al. Asia Hepatitis Lamivudine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:17280.
  • 5
    Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:8036.
  • 6
    Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine pretreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:10827.
  • 7
    Atkins M, Hunt CM, Brown N, et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients [Abstract]. Hepatology 1998;28:319A.
  • 8
    Colonno RJ, Rose RE, Levine SM, et al. Entecavir Two Year Resistance Update: No Resistance Observed in Nucleoside Naïve Patients and Low Frequency Resistance Emergence in Lamivudine Refractory Patients. 56th Annual Meeting of AASLD. San Francisco, CA. Nov 1115, 2005. Poster 962.
  • 9
    Lai CL. The Natural History and Treatment of CHB; Controversies and Consensus. Leon Schiff State of the Art Lecture – AASLD San Francisco. 1115, Nov, 2005. Available from:[Accessed January, 2006].
  • 10
    Chen CJ, Yan HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B Virus DNA level. JAMA 2006;295:6573.
  • 11
    Iloeje UH, Yang HI, Su J, et al. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:67886.
  • 12
    Chen CJ, Yang HI, Su J, et al. Elevated serum level of hepatitis B virus (HBV) DNA is an independent risk factor for Hepatocellular carcinoma: a long term follow-up study in Taiwan. Oral presentation 40th European Society for the Study of Liver Meeting. Paris, April 13–17th 2005. J Hepatol 2005;42(Suppl. 2):167.
  • 13
    Yang HI, Iloeje UH, Su J, et al. Progression to decompensate cirrhosis in chronic hepatitis B virus infected persons is strongly associated with baseline viral load. Poster presentation 40th European Society for the Study of Liver Meeting. Paris, April 13–17th 2005 EASL. J Hepatol 2005;42(Suppl. 2):195.
  • 14
    Yuan Y, Iloeje U, Hay J, Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008;14:2133.
  • 15
    Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother 2007;60:2015.
  • 16
    China Statistical Yearbook. Beijing: China Statistics Press, 2004.
  • 17
    The Vital Statistics of China. Beijing: Ministry of Health, 2004.
  • 18
    Durand-Zaleski I, Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventive strategies. Med Decis Making 1994;14: 98103.
  • 19
    Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:2519.
  • 20
    Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:288695.
    Direct Link:
  • 21
    Levy AR, Kowdley KV, Iloeje UH, et al. The impact of chronic hepatitis B disease progression on quality of life: a multinational study of health state preferences from infected and uninfected persons. Value Health 2008 (Online Early Articles).
  • 22
    Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003;38:126773.
  • 23
    Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142:82131.
  • 24
    Lok AS, McMahon BJ. American association for the study of liver diseases practice guidelines: chronic hepatitis B. American Association for the Study of Liver Diseases website [updated December, 2003]. Available from:[Accessed October 13, 2004].
  • 25
    Hay J. Where's the value in health care? Value Health 2006;9:13.
  • 26
    WHO. Macroeconomics and Health: Investing in Health for Economic Development-Report of the Commission on Macroeconomics and Health. Geneva, Switzerland: World Health Organization, 2001.
  • 27
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:93662.
  • 28
    Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797803.
    Direct Link:
  • 29
    Tang B, Kruger WD, Chen G, et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004; 72:3540.
  • 30
    Mahmood S, Niiyama G, Kamei A, et al. Influence of viral load and genotype in the progression of hepatitis B-associated liver cirrhosis to hepatocellular carcinoma. Liver Int 2005;25:2205.
  • 31
    Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005;16:26572.
  • 32
    Ohkubo K, Kato Y, Ichikawa T, et al. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular. Cancer 2002;94:26638.
  • 33
    Ohata K, Hamasaki K, Toriyama K, et al. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Clin Gastroenterol Hepatol 2004;19:6705.
  • 34
    Mommeja-Marin H, Mondou E, Blum R, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003;37:130919.
  • 35
    Marco VD, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:88391.
  • 36
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:8007.
  • 37
    Qi X, Snow A, Thibault V, et al. Long-term incidence of adefovir diprivoxil resistance in chronic hepatitis B patients after 144 weeks of therapy [Abstract]. J Hepatol 2004;40:57-A.
  • 38
    Sherman M, Yurdaydin C, Sollano J, et al. AI463026 BEHoLD Study Group. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:203949.
  • 39
    Lai CL, Shouval D, Lok AS, et al. BeHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:101120.
  • 40
    Lai CL, Chien RN, Leung NW, et al. Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339: 618.
  • 41
    Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:24050.
  • 42
    Tassopoulos NC, Volpes R, Pastore G, et al. Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:88996.
  • 43
    Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensate cirrhosis. J Hepatol 2000;33:30812.
  • 44
    Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensate cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:4116.
  • 45
    Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensate cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:3017.
  • 46
    Nikolaidis N, Vassiliadis T, Giuleme O, et al. Effect of lamivudine treatment in patients with decompensate cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005;19:3216.
  • 47
    Hann HW, Fontana RJ, Wright T, et al. United States Lamivudine Compassionate Use Study Group. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensate hepatitis B virus-related cirrhosis. Liver Transpl 2003;9:4956.
  • 48
    Tseng PL, Lu SN, Tung HD, et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensate liver cirrhosis. J Viral Hepat 2005;12:38692.
  • 49
    Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensate cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:20710.
  • 50
    Bae SH, Yoon SK, Choi JY, et al. Timing of lamivudine administration according to Child class in patients with decompensate cirrhosis. J Gastroenterol Hepatol 2005;20:152732.
  • 51
    Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensate liver disease caused by hepatitis B after treatment with lamivudine. Liver Transpl 2000;6:71520.
  • 52
    Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:20920.
  • 53
    Dai MS, Wu PF, Shyu RY, et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:5406.
  • 54
    Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004;11: 1417.
  • 55
    Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:23340.
  • 56
    Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:17429.
  • 57
    Lee GW, Ryu MH, Lee JL, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003;18: 84954.
  • 58
    Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002;16:193944.
  • 59
    Nagamatsu H, Itano S, Nagaoka S, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004;99:236975.
    Direct Link:
  • 60
    Yeo W, Ho WH, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:20915.
  • 61
    Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:92734.
  • 62
    Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005;28:37984.
  • 63
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:152131.
  • 64
    Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis. Aliment Pharmacol Ther 2007;26:38391.
  • 65
    Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007;147:5861.
  • 66
    Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44:28390.
  • 67
    Marcellin P, Change T-T, Lim S, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:80816.
  • 68
    Leung N, Peng C, Sollano J, et al. Entecavir results in greater HBV DNA reduction vs adefovir in chronically infected HBeAg(+) antiviral-naïve adults: 24-week results (E.A.R.L.Y. study). Hepatology 2006; 44(4 Suppl. 1):554A (Abstract 982).